PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurod…
Author: Business Wire
GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Systane se joint aux Blue Jays de Toronto à titre de goutte oculaire officielle pour sensibiliser les Canadiens à la sécheresse oculaire
TORONTO–(BUSINESS WIRE)–Cette saison, Alcon, le chef de file mondial en matière de soins oculaires qui se consacre à aider les gens à voir avec clarté, a annoncé un partenariat entre les Blue Jays de Toronto et SystaneMD en tant que gouttes oculaires…
Systane Steps Up to the Plate as the Official Eye Drop of the Toronto Blue Jays, Raising Awareness of Dry Eye in Canada
TORONTO–(BUSINESS WIRE)–This season, Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced that Systane® has partnered with the Toronto Blue Jays as the official eye drop of the team. The partnership aims to help…
ForSight Robotics Makes History with the World’s First-in-Human Fully Robot-Assisted Cataract Surgery
CAESAREA, Israel–(BUSINESS WIRE)–ForSight Robotics, the global pioneer in robotic eye surgery, today announced the successful completion of the world’s first fully robot-assisted cataract surgery performed in a human patient using its proprietary JAS…
Tenpoint Therapeutics, Ltd. Appoints Stephen S. Lane, M.D., as Chief Medical Officer
LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced the appointment of Stephen S. Lane…
Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European commercial availability of the preloaded enVista Envy ful…
Alcon Launches Clareon TruPlus, Enhanced Design Monofocal and Toric IOLs, at ASCRS 2026
FORT WORTH, Texas–(BUSINESS WIRE)–Alcon Launches Clareon TruPlus, Enhanced Design Monofocal and Toric IOLs, at ASCRS 2026
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that …
Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of new scientific data and events taking place du…
Alcon Publishes Agenda for 2026 Annual General Meeting
GENEVA–(BUSINESS WIRE)–Alcon Publishes Agenda for 2026 Annual General Meeting
Alcon Publishes Agenda for 2026 Annual General Meeting
GENEVA–(BUSINESS WIRE)–Alcon Publishes Agenda for 2026 Annual General Meeting
Tenpoint Therapeutics Ltd and PHIL Partner to Launch YUVEZZI™ Direct-to-Patient Cash Program to Make Novel Presbyopia Therapy More Accessible and Affordable
SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Tenpoint Therapeutics, a leading ophthalmic manufacturer, and PHIL Inc., an all-in-one digital hub and Direct-to-Patient platform, today announced the launch of a Direct-to-Patient (DTP) cash program for YUVEZZI™, th…
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of a pivotal Phase 2b/3 trial evaluating MK-8748 (also known as Tiespectus, EYE201), a novel investigational bispecif…
Ray Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RTx-015 in Retinitis Pigmentosa
BERKELEY, Calif.–(BUSINESS WIRE)–Ray Therapeutics (RayTx), a clinical-stage biopharmaceutical company pioneering optogenetic therapies for those living with retinal degenerative diseases, today announced that the U.S. Food and Drug Administration (FD…
Amprion Grows Global Footprint with Australian Partnership & Expanded Research Collaborations
SAN FRANCISCO–(BUSINESS WIRE)–Amprion Grows Global Footprint with Australian Partnership & Expanded Research Collaborations
Science Corp. Appoints Murat Günel, MD, as Medical Director for Brain-Computer Interfaces
ALAMEDA, Calif.–(BUSINESS WIRE)–Science Corporation, the full-stack neural engineering and brain-computer interface (BCI) company focused on restoring and extending life, today announced the appointment of Murat Günel, MD, as Medical Director for Bra…
Amaros Launches Interventional Glaucoma Network to Advance Evidence in Interventional Glaucoma
ATHERTON, Calif.–(BUSINESS WIRE)–Amaros Launches Interventional Glaucoma Network to Advance Evidence in Interventional Glaucoma
Amaros Launches Interventional Glaucoma Network to Advance Evidence in Interventional Glaucoma
ATHERTON, Calif.–(BUSINESS WIRE)–Amaros Launches Interventional Glaucoma Network to Advance Evidence in Interventional Glaucoma
MightyMeals CEO Stefano Marzano Reunites with Children's National Doctor Who Helped Restore His Vision
WASHINGTON–(BUSINESS WIRE)–MightyMeals CEO and Executive Chef Stefano Marzano recently reunited with Dr. Marijean Miller of Children’s National Hospital, the ophthalmologist who treated him from infancy through age 18 after he was born blind—a moment…